ClinicalTrials.gg
CompletedNCT00202020Updated Mar 16, 2006

Efficacy and Safety Study of Cilostazol to Prevent Reoccurrence of Stroke

A Phase 3 interventional study of Cilostazol 200mg/day Oral and Aspirin 100mg/day Oral in Cerebral Infarction, sponsored by Otsuka Beijing Research Institute. Completed at 12 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2006-03-16.

Sponsored by Otsuka Beijing Research Institute (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
720
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing cilostazol in Cerebral Infarction — 1 open to participants now, 1 under way, none of them phase 3. Cilostazol · Cerebral Infarction.

Enrollment
5th of 10
720 · median 594
Started
2004
the only one that year
Phase 3
2 of 10
none open now
Registered
2nd of 10
by date
Lead sponsor
2 of 10
Otsuka Beijing Research Institute

Among the 10 studies testing cilostazol in Cerebral Infarction, this one is the 5th largest by enrollment, is the only one that started in 2004, is one of 2 in phase 3, and was the 2nd registered.

Cerebral Infarction

219 studies on the registry are indexed under Cerebral Infarction; 46 are open to participants now.

Browse Cerebral Infarction studies →

Open to participants now

1 of the 10 studies testing cilostazol in Cerebral Infarction is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About cilostazol

Cilostazol: first FDA approval 1999 (PLETAL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 27 Cerebral Infarction studies recruiting now, 19 (70%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing cilostazol in Cerebral Infarction, or all of them as a file.
02

Study summary

The study design is subject to relevant SFDA regulations about clinical trials. This indication was approved in Japan in 2003.

From the end of May 2004 to the end of Dec. 2004, 720 patients with previous cerebral infarction(see the inclusion criteria) were enrolled in to the study and received one of the two treatment regimens, Cilostazol or Aspirin, the ratio of patient number of each group is 1:1. For each patient, the chance of entering either of these two groups is the same. The treatment will continue till the end of 2005. During the treatment period, patients will be observed concerning some certain events, mainly reoccurrence of stroke. If the patient experiences reoccurrence of stroke, or other event that the doctors think it is not appropriate to continue the study medication, this patient would stop the treatment. Patients were also required to take MRI head scan before entering the study and on completion of the treatment.

03

Conditions studied

  • Cerebral Infarction

Keywords

  • Cerebral infarction
  • Prevention
  • Cilostazol
  • Aspirin
  • Stroke
  • Clinical trial
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients who had cerebral infarction within 6 months and 1 month before entry 2. Within a few days of the onset of cerebral infarction onset, CT or MRI showed evidence of infarction that could be responsible for this stroke onset 3. A modified ranking scale of less than 4 4. Aged 18\~75 5. Consent of the patients or their legal guardians

Exclusion criteria

-

Exclusion Criteria:

  1. History of intracranial hemorrhage 2. Stroke secondary to cardiogenic embolism 3. Serious damage of motorial function, dementia 4. Serious complications or co morbidity(uncontrolled accelerated type of hypertension, BP>180/120mmHg, diabetic acidosis, heart failure, renal failure, hepatocirrhosis, malignant tumor) 5. of Cilostazol and Aspirin 6. Patients who need co medication of other antiplatelet agents, anticoagulants or fibrinolytic drugs 7. Active peptic ulcer 8. Pregnancy or breast feeding 9. Judged to be inappropriate to enter the study by investigators. -

-

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
720 participants

Interventions

  • DrugCilostazol 200mg/day Oral

    Drug page: Cilostazol

  • DrugAspirin 100mg/day Oral

    Drug page: Aspirin

06

What researchers measure

Primary outcomes

  1. Recurrence of stroke(cerebral infarction/haemorrhage/subarachnoid haemorrhage)

Secondary outcomes

  1. Recurrence of cerebral infarction detected in MRI

  2. Death due to cerebral vascular events

  3. Myocardial infarction

  4. Vascular events(acute artery thrombosis/embolism, pneumonia embolism, venous thrombosis, angina pectoris)

  5. TIA

  6. Death

07

Study locations

12 sites
  • 1st affiliated hospital, Guangzhou Zhongshan University
    Guangzhou, Guangdong, China
  • 2nd affiliated hospital, Guangzhou medical college
    Guangzhou, Guangdong, China
  • 1st affiliated Jilin University
    Changchun, Jilin, China
  • 1st affiliated hospital, Xi'an Jiatong University
    Xi'an, Shanxi, China
  • 2nd affiliated hospital, Zhejiang University
    Hangzhou, Zhejiang, China
  • 1st affiliated hospital, Peking University
    Beijing, China
  • 3rd affiliated hospital, Peking University
    Beijing, China
  • General Hospital of Beijing Military Area of PLA
    Beijing, China
  • Renmin Hospital, Peking University
    Beijing, China
  • Huashan Hospital Shanghai Fudan University
    Shanghai, China
  • Renji Hospital, Shanghai 2nd medical university
    Shanghai, China
  • General Hospital, Tianjin Medical University
    Tianjin, China
08

References and documents

Publications

  • Liu W, Liu R, Sun W, Peng Q, Zhang W, Xu E, Cheng Y, Ding M, Li Y, Hong Z, Wu J, Zeng J, Yao C, Huang Y; CASISP Study Group. Different impacts of blood pressure variability on the progression of cerebral microbleeds and white matter lesions. Stroke. 2012 Nov;43(11):2916-22. doi: 10.1161/STROKEAHA.112.658369. Epub 2012 Sep 4. PubMed 22949472 ↗
  • Huang Y, Cheng Y, Wu J, Li Y, Xu E, Hong Z, Li Z, Zhang W, Ding M, Gao X, Fan D, Zeng J, Wong K, Lu C, Xiao J, Yao C; Cilostazol versus Aspirin for Secondary Ischaemic Stroke Prevention cooperation investigators. Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study. Lancet Neurol. 2008 Jun;7(6):494-9. doi: 10.1016/S1474-4422(08)70094-2. Epub 2008 May 2. Erratum In: Lancet Neurol. 2008 Aug;7(8):675. PubMed 18456558 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2004 and a completion of Jan 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2005
First posted
Sep 20, 2005
Start
May 2004
Completion
Jan 2006
Last update
Mar 16, 2006
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on Mar 16, 2006, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00202020
Collaborators
Zhejiang Otsuka Pharmaceutical Co., Ltd.
First posted
Sep 20, 2005
Start date
May 2004
Completion
Jan 2006
Last update
Mar 16, 2006

Study contacts

Yi N Huang, Professor
principal investigator · Peking University First Hospital
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2006. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cilostazol

Start the discussion